Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
National Institutes of Health (NIH)
Biotech
Former CBER chief Peter Marks leaps to Lilly—Chutes & Ladders
Former CBER chief Peter Marks leaps to Lilly. OSE swaps out CEO. Mikael Dolsten settles into board chair at cancer biotech.
Darren Incorvaia
,
Zoey Becker
Oct 10, 2025 8:30am
Leader of NIAID fired in alleged whistleblower retaliation
Oct 3, 2025 12:12pm
NIH research grinds to a halt as government shuts down
Oct 1, 2025 12:12pm
White House pledges $100M to AI pediatric cancer project
Oct 1, 2025 11:06am
Dana-Farber oncologist Anthony Letai tapped to direct NCI
Sep 30, 2025 5:50am
Alternate history of NIH reveals potential impact of agency cuts
Sep 25, 2025 2:00pm
